Expression of A New Endogenous Retrovirus-Associated Transcript in Hodgkin Lymphoma Cells.

Int J Mol Sci

Department of Surgical and Conservative Pediatrics and Adolescent Medicine, Martin Luther University Halle-Wittenberg, 06097 Halle, Germany.

Published: October 2019

During characterization of a cDNA library from the Hodgkin lymphoma (HL) cell line L-1236, we discovered a new transcript derived from chromosome 1 at the long intergenic non-protein coding RNA 1768 (LINC01768)/colony stimulating factor 1 (CSF1) region. The first exon of this transcript from Hodgkin lymphoma cells (THOLE) starts in the predicted exon 4 of LINC01768 and is part of an endogenous retrovirus (ERV) from the HUERS-P1/LTR8 family. High expression of THOLE was only detectable in HL cell line L-1236. The expression of THOLE in L-1236 cell is another example for ERV/LTR-associated gene expression in HL cells. At the genome level, the HUERS-P1/LTR8 region including THOLE is only present in Hominoidea. The influence of ERV/LTRs on gene expression might explain the characteristic phenotype of human HL.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862598PMC
http://dx.doi.org/10.3390/ijms20215320DOI Listing

Publication Analysis

Top Keywords

hodgkin lymphoma
12
transcript hodgkin
8
lymphoma cells
8
cell l-1236
8
expression thole
8
gene expression
8
expression
5
expression endogenous
4
endogenous retrovirus-associated
4
retrovirus-associated transcript
4

Similar Publications

Maternal immunization is an important tool directed against a variety of infectious maladies in the offspring. A complementary, but less explored area is the use of maternal immunization in the prevention and treatment of childhood cancers. This in part stems from the lack of adequate experimental model systems.

View Article and Find Full Text PDF

Primary uterine non-Hodgkin lymphoma (NHL) is rarely reported, as its incidence is extremely low. We describe a 72 year old patient with primary uterine non-Hodgkin's lymphoma stage IV, diffuse B-cell large cells, who responded well to cytotoxic chemotherapy (R-CHOP). Radiological investigations exhibited certain characteristics, including magnetic resonance T2 weighted imaging, enhanced scanning, diffusion weighted imaging and apparent diffusion coefficient values.

View Article and Find Full Text PDF

Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives.

Leuk Lymphoma

January 2025

First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany.

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity accounting for ≈5% of all Hodgkin lymphoma (HL) cases. As some characteristics of NLPHL resemble B-cell non-Hodgkin lymphoma (B-NHL), nodular lymphocyte-predominant B-cell lymphoma has been proposed as alternative name. Unlike classical HL (cHL), NLPHL is mostly diagnosed in early stages.

View Article and Find Full Text PDF

Introduction And Importance: Orbital lymphomas, are extranodal lymphomas primarily involving the ocular adnexa, which includes conjunctiva, eyelids, eyelashes, eyebrows, lacrimal glands, retro-orbital soft tissues, and the extraocular muscles. Ocular adnexal lymphomas can be primary or secondary. This case is important because there are few case reports in the world, and it is among the first case to be reported from Ethiopia.

View Article and Find Full Text PDF

Background/aim: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma worldwide. Patients can have a wide range of clinical features and behavior which does not necessarily correlate to histologic grade or Ki-67 proliferation index. We hypothesized that patients with low grade but high proliferative index (LG/HP) FL have a more aggressive disease course.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!